The study contains Phase 1A and Phase 1B. Phase 1A has Part1 (BID Dose Escalation) and Part2
(QD Dosing Escalation) Evaluation of a cohort of at least three participants completing one
cycle of treatment at that dose level and dose regimen is required prior to determining the
next dose level and dose regimen for the next cohort. Phase 1B has PartA (BID Dosing
Expansion) will investigate efficacy in participants with selected tumor types and further
evaluate safety and tolerability of BGB 290 at recommended dose for future studies. and PartB
(Food Effect) will investigate the food effect on the Pharmacokinetics (PK) of BGB 290 in
participants with advanced solid tumors.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.